Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer

NCT04991948 is registered in ClinicalTrials.gov with Celyad Oncology SA as lead sponsor.

NCT NCT04991948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04991948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer
Lead sponsor
Celyad Oncology SA
Phase
Phase 1
Overall status
Recruiting
Start date
November 22, 2021
Completion date
May 25, 2038
Enrollment
34 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable metastatic colorectal cancer